Safety Pharmacology Validation Data Review

In this concise 10-minute on-demand video presentation, Dr. Michael R. Gralinski, CEO of CorDynamics, reviews the results of three safety pharmacology validation studies conducted in 2020 at Altasciences’ state-of-the-art telemetry facility. These studies were designed to validate GLP Safety Pharmacology service offerings using telemetered dogs and well-characterized positive controls to assess hemodynamic, electrocardiographic, and respiratory responses. The results of the studies demonstrated a high degree of fidelity in detecting the expected effects of the positive controls: Verapamil (0, 1.5, 15 mg/kg) for hemodynamics, Doxapram (0, 1.5, 4 mg/kg) for respiratory effects, and Dofetilide (0, 0.1, 0.3 mg/kg) for electrocardiography and arrhythmias.

About the Presenter
Dr. Michael R. Gralinski is the Chief Executive Officer and Co-founder of CorDynamics, a leading cardiovascular contract research organization based in Chicago. With extensive experience in pharmaceutical development encompassing product safety, toxicology, and safety pharmacology, Dr. Gralinski is a former President of the Safety Pharmacology Society. He holds a B.S. in Pharmacology and Toxicology from the University of Wisconsin-Madison and a Ph.D. in Cardiovascular Pharmacology from the University of Michigan, bringing unparalleled expertise to this presentation.